Topical drug bioavailability, bioequivalence, and penetration:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York u.a.
Plenum Press
1993
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXII, 453 S. Ill., graph. Darst. |
| ISBN: | 0306443678 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV009686062 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 940705s1993 ad|| |||| 00||| engod | ||
| 020 | |a 0306443678 |9 0-306-44367-8 | ||
| 035 | |a (OCoLC)28722190 | ||
| 035 | |a (DE-599)BVBBV009686062 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a RM151 | |
| 082 | 0 | |a 615/.6 |2 20 | |
| 084 | |a VX 7580 |0 (DE-625)147815:253 |2 rvk | ||
| 245 | 1 | 0 | |a Topical drug bioavailability, bioequivalence, and penetration |c ed. by Vinod P. Shah ... |
| 264 | 1 | |a New York u.a. |b Plenum Press |c 1993 | |
| 300 | |a XXII, 453 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Biodisponibilité | |
| 650 | 7 | |a Biologische beschikbaarheid |2 gtt | |
| 650 | 7 | |a Geneesmiddelentransport |2 gtt | |
| 650 | 4 | |a Médicaments - Équivalence thérapeutique | |
| 650 | 4 | |a Peau - Perméabilité | |
| 650 | 4 | |a Thérapeutique cutanée et externe | |
| 650 | 7 | |a Transdermale toediening |2 gtt | |
| 650 | 4 | |a Administration, Topical | |
| 650 | 4 | |a Bioavailability | |
| 650 | 4 | |a Biological Availability | |
| 650 | 4 | |a Drug Delivery Systems | |
| 650 | 4 | |a Drugs |x Therapeutic equivalency | |
| 650 | 4 | |a Skin Absorption | |
| 650 | 4 | |a Skin |x Permeability | |
| 650 | 4 | |a Therapeutic Equivalency | |
| 650 | 4 | |a Therapeutics, Cutaneous and external | |
| 650 | 0 | 7 | |a Transdermales therapeutisches System |0 (DE-588)4194948-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Bioäquivalenz |0 (DE-588)4204145-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Bioverfügbarkeit |0 (DE-588)4145660-9 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Transdermales therapeutisches System |0 (DE-588)4194948-1 |D s |
| 689 | 0 | 1 | |a Bioverfügbarkeit |0 (DE-588)4145660-9 |D s |
| 689 | 0 | 2 | |a Bioäquivalenz |0 (DE-588)4204145-4 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Shah, Vinod P. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006405650&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006405650 | ||
Datensatz im Suchindex
| _version_ | 1804124030982160384 |
|---|---|
| adam_text | TOPICAL DRUG BIOAVAILABILITY, BIOEQUIVALENCE, AND PENETRATION EDITED BY
VINOD P. SHAH FOOD AND DRUG ADMINISTRATION ROCKVILLC. MARYLAND AND
HOWARD I. MAIBACH UNIVERSITY OF CALIFORNIA SUN FRANCISCO. CALIFORNIA
PLENUM PRESS * NEW YORK AND LONDON CONTENTS PARTI TOPICAL DRUG DELIVERY
CHAPTER 1 PERCUTANEOUS ABSORPTION RONALD C. WESTER AND HOWARD I. MAIBACH
1. INTRODUCTION 3 2. POWDERED HUMAN STRATUM CORNEUM 4 3. IN VITRO
PERCUTANEOUS ABSORPTION METHOD 5 4. IN VITRO INDIVIDUAL AND REGIONAL
VARIATION 7 5. IN VITRO SHORT-TERM SKIN EXPOSURE 9 6. IN VIVO
PERCUTANEOUS ABSORPTION METHODS 10 6.1. SKIN STRIPPING: SHORT-TERM
EXPOSURE 10 6.2. SKIN FLAPS 11 6.3. SYSTEMIC BIOAVAILABILITY (BLOOD AND
EXCRETA) 12 6.4. SURFACE DISAPPEARANCE 13 6.5. BIOLOGICAL RESPONSE 13
REFERENCES 14 CHAPTER 2 TRANSDERMAL DELIVERY SYSTEMS: A MEDICAL
RATIONALE GARY W. CLEARY 1. INTRODUCTION 17 2. PHARMACOKINETIC
INTERPRETATION 21 3. SELECTION OF SUITABLE DRUG CANDIDATES 28 4.
PHARMACEUTICS CONSIDERATIONS 30 4.1. DESIGN OF TRANSDERMAL DELIVERY
SYSTEMS 30 4.2. REGULATORY CONSIDERATIONS 34 II CONTENTS 5. COMMERCIAL
TRANSDERMAL DRUG DELIVERY SYSTEMS 35 5.1. SCOPOLAMINE TRANSDERMAL
SYSTEMS 35 5.2. NITROGLYCERIN TRANSDERMAL SYSTEMS 37 5.3. CLONIDINE
TRANSDERMAL SYSTEMS 44 5.4. ESTRADIOL TRANSDERMAL SYSTEMS 47 5.5.
FENTANYL TRANSDERMAL SYSTEMS 50 5.6. NICOTINE TRANSDERMAL SYSTEMS 52 6.
HOW TRANSDERMAL DRUG DELIVERY HAS PERFORMED 57 6.1. DIFFERENT
THERAPEUTIC AREAS 57 6.2. ADVANTAGE OVER CURRENT DOSAGE FORMS 57 6.3.
DIFFERENT RATIOS OF METABOLITES AND LIPIDS: ESTRADIOL TRANS- DERMAL
VERSUS ORAL 58 6.4. DRUGS WITH DIFFICULT-TO-FORMULATE PROPERTIES 58 6.5.
DIFFERENT BLOOD-LEVEL PROFILES FROM OTHER DOSAGE FORMS 58 6.6. LINEAR
RELATION OF BLOOD LEVEL TO AREA OF SYSTEM 59 6.7. DIFFERENT DELIVERY AND
WEARING TIME 59 6.8. SAME BLOOD LEVELS WITH DIFFERENT DESIGNS 59 6.9.
SAME BLOOD LEVELS WITH DIFFERENT MECHANISMS 59 6.10. OTHER DRUGS 60
6.11. INTERMITTENT DELIVERY 61 6.12. ELECTRICALLY ENHANCED PERMEATION 62
REFERENCES 63 CHAPTER 3 PRODRUGS AND THEIR TOPICAL USE BRADLEY D.
ANDERSON 1. INTRODUCTION 69 2. SELECTIVITY OF THE STRATUM CORNEUM TO
PERMEANT STRUCTURE 71 2.1. POLAR PATHWAY 72 2.2. LIPID PATHWAY 73 3.
DESIGN OF PRODRUGS TO OPTIMIZE MAXIMUM FLUX 80 REFERENCES 87 CHAPTER 4
ULTRASOUND-MEDIATED TRANSDERMAL DRUG DELIVERY JOSEPH KOST AND ROBERT
HANGER 1. INTRODUCTION 91 2. ULTRASOUND CHARACTERISTICS 92 CONTENTS XIII
2.1. PROPERTIES OF THE ULTRASOUND BEAM 93 2.2. NATURE OF THE ULTRASOUND
WAVE 93 2.3. MASS DENSITY AND ACOUSTIC IMPEDANCE 93 2.4. ABSORPTION AND
PENETRATION OF ULTRASOUND 94 3. CLINICAL STUDIES 94 4. NONHUMAN IN VIVO
STUDIES 96 5. ULTRASOUND FOR TRANSDERMAL DELIVERY SYSTEMS 96 6.
MECHANISM 98 7. CONCLUSIONS 101 REFERENCES 101 PART II IN VITRO
METHODOLOGY CHAPTER 5 PRACTICAL CONSIDERATIONS IN DEVELOPING A QUALITY
CONTROL (IN VITRO RELEASE) PROCEDURE FOR TOPICAL DRUG PRODUCTS VINOD P.
SHAH AND JEROME P. SKELLY 1. INTRODUCTION 107 2. IN VITRO RELEASE
METHODS FOR TRANSDERMAL PATCHES 109 3. IN VITRO RELEASE METHOD FOR
CREAMS. OINTMENTS, AND GELS 110 4. CONCLUSIONS 115 REFERENCES 115
CHAPTER 6 DIFFUSION CELL DESIGN ROBERT L. BRONAUGH 1. TWO-CHAMBERED CELL
117 2. ONE-CHAMBERED CELL 118 2.1. STATIC DIFFUSION CELL DESIGN 118 2.2.
FLOW-THROUGH DIFFUSION CELL DESIGN M9 3. VALIDATION OF THE FLOW-THROUGH
CELL 122 4. MODIFICATIONS 123 5. CONCLUSIONS 124 REFERENCES 124 CONTENTS
PART III IN VIVO METHODOLOGY CHAPTER 7 CUTANEOUS BIOAVAILABILITY,
BIOEQUIVALENCE, AND PERCUTANEOUS ABSORPTION: IN VIVO METHODS, PROBLEMS,
AND PITFALLS /. C. JAMOULLE AND H. SCHAEFER 1. INTRODUCTION 129 1.1.
DEFINITIONS AND RELATIONSHIPS BETWEEN CUTANEOUS BIOAVAIL- ABILITY,
BIOEQUIVALENCE, AND PERCUTANEOUS ABSORPTION 129 1.2. GUIDANCE AND
DEFINITIONS FROM REGULATORY PUBLICATIONS ... 130 2. IN VIVO STRATEGY AND
METHODOLOGY: PROBLEMS AND PITFALLS 132 2.1. IN VIVO METHODS IN ANIMALS
133 2.2. IN VIVO METHODS IN HUMANS 138 3. CONCLUSION 141 REFERENCES I 47
CHAPTER 8 THE HUMAN SKIN BLANCHING ASSAY FOR TOPICAL CORTICOSTEROID
BIOAVAILABILITY ASSESSMENT ERIC W. SMITH, ERIC MEYER, AND JOHN M. HAIGH
1. INTRODUCTION 155 2. BLANCHING TRIAL METHODOLOGY 156 3. OBSERVATION OF
RESULTS 157 3.1. SINGLE VERSUS MULTIPLE OBSERVATIONS 157 3.2. EYE OR
INSTRUMENT OBSERVATIONS 158 3.3. OBSERVER TRAINING 159 4. CLINICAL
EQUIVALENCY OF FORMULATIONS 159 5. CONCLUSIONS 161 REFERENCES 161
CHAPTER 9 PREDICTIVE APPROACHES I: THE STRIPPING TECHNIQUE A. ROUGIER
AND C. LOTTE 1. INTRODUCTION 163 2. IN VIVO RELATIONSHIP BETWEEN STRATUM
CORNEUM CONCENTRATION AND PERCUTANEOUS ABSORPTION 164 CONTENTS XV 3.
INFLUENCE OF APPLICATION CONDITIONS ON THE RELATIONSHIP BETWEEN STRATUM
CORNEUM CONCENTRATION AND PERCUTANEOUS ABSORPTION . . 166 3.1. INFLUENCE
OF DOSE APPLIED 167 3.2. INFLUENCE OF VEHICLE 167 3.3. INFLUENCE OF
APPLICATION TIME 174 3.4. INFLUENCE OF ANATOMICAL LOCATION 175 4.
CONCLUSION 177 REFERENCES 180 CHAPTER 10 PREDICTIVE APPROACHES II:
MASS-BALANCE PROCEDURE DANIEL A. W. BUCKS 1. INTRODUCTION 183 2.
MATERIALS AND METHODS 184 3. RESULTS 186 3.1. PERCUTANEOUS ABSORPTION OF
STEROIDS IN HUMANS 186 3.2. PERCUTANEOUS ABSORPTION OF PHENOLS IN HUMANS
186 3.3. RELATIONSHIPS BETWEEN PARTITIONING AND EXTENT OF PERCUTANEOUS
ABSORPTION IN HUMANS 189 3.4. RELATIONSHIPS BETWEEN PARTITIONING AND
AMOUNT OFCOMPOUND RECOVERED BY SURFACE WASHING 189 3.5. RELATIONSHIPS
BETWEEN PENETRANT PARTITIONING AND RETENTION IN THE STRATUM CORNEUM 190
4. DISCUSSION 192 REFERENCES 194 CHAPTER 11 IN VIVO TOPICA L
BIOAVAILABILITY AND SKIN DECONTAMINATION: EXAMPLE ALACHLOR RONALD C.
WESTER AND HOWARD 1. MAIHACH 1. INTRODUCTION 19? 2. METHODS 198 2.1.
PERCUTANEOUS ABSORPTION 198 2.2. SKIN DECONTAMINATION 199 2.3.
SCINTILLATION COUNTING 199 3. RESULTS 200 4. DISCUSSION 204 REFERENCES
206 XV J CONTENTS CHAPTER 12 GRAFTED SKIN AND SKIN FLAPS J. EDMOND
RIVIERE 1. INTRODUCTION 209 2. GRAFTED SKIN MODELS 210 2.1. INTACT
RODENT MODELS 210 2.2. THE RAT/HUMAN SKIN FLAP SYSTEM (RHSFS) 211 3. THE
ISOLATED PERFUSED PORCINE SKIN RAP (IPPSF) 212 3.1. PROCEDURE FOR
CREATING IPPSFS 212 3.2. ISOLATED PERFUSION PROTOCOLS 213 3.3.
PERCUTANEOUS ABSORPTION STUDIES 214 3.4. IN VITRO TO IN VIVO PREDICTIONS
216 3.5. ROLE OF ISOLATED TISSUE SYSTEMS IN DERMATOPHARMACOKINETICS 218
4. DISCUSSION 218 REFERENCES 219 PART IV FACTORS INFLUENCING
PERCUTANEOUS TRANSPORT CHAPTER 13 IN VIVO AND IN VITRO SKIN UPTAKE AND
PERMEATION STUDIES: CRITICAL CONSIDERATIONS AND FACTORS WHICH AFFECT
THEM CHARAN R. BEHL, HING CHAR, SUNIL B. PATE/, DEEPAK B. MEHTA, DAVID
PIEMONTESE, AND A. WASEEM MALICK 1. INTRODUCTION 225 2. SKIN-RELATED
PRODUCTS: DEFINITIONS AND OBJECTIVES 226 2.1. TRANSDERMAL PRODUCTS 226
2.2. DERMATOLOGICAL PRODUCTS 226 3. DEVELOPMENT OF TRANSDERMAL PRODUCTS
226 3.1. FEASIBILITY STUDIES 227 3.2. FORMULATION STUDIES 227 3.3.
DESIGN OF DRUG DELIVERY SYSTEMS (THE HARDWARE ) 227 3.4. CLINICAL
STUDIES 227 3.5. OPTIMIZATION: FEEDBACK PROCESS 227 4. DEVELOPMENT OF
DERMATOLOGICAL PRODUCTS 228 4.1. SCREENING OF VEHICLES FOR DRUG UPTAKE
IN THE SKIN 228 4.2. FORMULATION STUDIES 228 4.3. CLINICAL STUDIES 229
4.4. OPTIMIZATION: FEEDBACK PROCESS 229 CONTENTS XVII 5. DRUG UPTAKE
STUDIES*RATIONALE AND OBJECTIVES 229 6. IN VITRO VERSUS IN VIVO DRUG
UPTAKE STUDIES: A FOUR-PRONG APPROACH 229 6.1. TRANSDERMAL PRODUCTS 230
6.2. DERMATOLOGICAL PRODUCTS 230 7. MODELS AND MEMBRANES FOR THE STUDY
OF DRUG UPTAKE AND PERMEATION IN AND THROUGH THE SKIN 231 7.1.
CHARACTERISTICS OF GOOD MODELS: A FOUR-PRONG APPROACH . . 231 7.2.
MEMBRANES 232 8. ROLE OF TEST COMPOUNDS IN STUDYING DRUG UPTAKE AND
PERMEATION 235 9. FACTORS WHICH AFFECT DRUG UPTAKE AND PERMEATION 236
9.1. HYDRATION 238 9.2. LIPOPHILICITY AND MOLECULAR WEIGHT OF PERMEANTS
238 9.3. DRUG SOLUBILITY AND CONCENTRATION 241 9.4. EFFECTS OF
VEHICLE/DOSAGE FORM 243 9.5. SITE, AGE, GENDER, AND RACE 246 9.6.
ENHANCERS 247 10. RECOMMENDATIONS 251 REFERENCES 252 CHAPTER 14 VEHICLE
EFFECT: WHAT IS AN ENHANCER? B. W. BARRY 1. INTRODUCTION 261 2. NATURE
OF DERMATOLOGICAL VEHICLES 261 2.1. LIQUID PREPARATIONS 262 2.2. SIMPLE
SUSPENSIONS 263 2.3. EMULSIONS 264 2.4. TRANSDERMAL DRUG DELIVERY
DEVICES 266 3. POSSIBLE EFFECTS OF VEHICLE ON STRATUM CORNEUM 267 3.1.
HORNY LAYER UNMODIFIED*CHEMICAL POTENTIAL ADJUSTMENT 267 3.2. HORNY
LAYER MODIFIED 268 REFERENCES 275 CHAPTER 15 THE DOSE RESPONSE OF
PERCUTANEOUS ABSORPTION RONALD C. WESTER AND HOWARD I. MAIBACH 1.
INTRODUCTION 277 2. ACCOUNTABILITY (MASS BALANCE) 279 X CONTENTS 3.1.
HUMAN SUBJECT POPULATION 353 3.2. TOPICAL DRUG APPLICATION 354 3.3.
ANALYTICAL METHODS 355 3.4. SKIN BLANCHING ASSAY 356 3.5. CORRELATION
BETWEEN AMOUNT OF TOPICAL DRUG IN THE HUMAN STRATUM CORNEUM AND SKIN
BLANCHING ASSAY IN VIVO 357 4. IN VITRO DRUG UPTAKE INTO HUMAN STRATUM
CORNEUM 358 4.1. SKIN PREPARATION 358 4.2. TOPICAL DRUG APPLICATION 358
4.3. IN VITRO RESULTS 359 5. IN VITRO DRUG RELEASE ACROSS SYNTHETIC
MEMBRANES 359 5.1. METHODS 359 5.2. DRUG RELEASE FROM OINTMENT
FORMULATIONS 360 5.3. DRUG RELEASE FROM CREAM FORMULATIONS 361 6. IN
VIVO/IN VITRO COMPARISONS OF DRUG UPTAKE AND RELEASE 362 6.1. OINTMENT
FORMULATIONS 362 6.2. CREAM FORMULATIONS 363 6.3. COMPARISON OF THREE
MODEL SYSTEMS 363 7. SUMMARY 364 REFERENCES 365 PART VI BIOPHARMACEUTICS
AND CLINICAL ASSESSMENT CHAPTER 20 GENERAL INTRODUCTION AND CONCEPTUAL
DIFFERENTIATION OF TOPICAL AND TRANSDERMAL DRUG DELIVERY SYSTEMS:
DIFFERENTIATION WITH RESPECT TO DELIVERY KINETICS GORDON L. FLYNN 1.
FUNDAMENTAL DEFINITIONS: TOPICAL AND TRANSDERMAL SYSTEMS .... 370 2.
THERMODYNAMIC AND KINETIC FACTORS OF TOPICAL DELIVERY 378 2.1. KINETIC
DETERMINANTS OF DELIVERY 381 2.2. THERMODYNAMIC DETERMINANTS OF DELIVERY
385 3. SUMMARY 390 REFERENCES 391 CONTENTS XXI CHAPTER 21 BIOEQUIVALENCE
OF TOPICAL DERMATOLOGICAL PRODUCTS VINOD P. SHAH, DONALD HARE, SHRIKANT
V. DIGHE, AND ROGER L. WILLIAMS 1. INTRODUCTION 393 2. GENERIC TOPICAL
DERMATOLOGICAL PRODUCTS: REGULATORY HISTORY . . . 395 3. PHARMACEUTICAL
AND THERAPEUTIC EQUIVALENCE: CRITERIA FOR GENERIC SUBSTITUTION 396 4.
DOCUMENTATION OF BIOEQUIVALENCE: IN VITRO ISSUES 397 4.1. SYNTHETIC
MEMBRANES 398 4.2. NATURAL MEMBRANES 400 5. DOCUMENTATION OF
BIOEQUIVALENCE: IN VIVO ISSUES 401 5.1. ANIMAL MODELS 401 5.2.
PHARMACOKINETIC METHODOLOGY 402 5.3. PHARMACODYNAMIC STUDIES 405 5.4.
CLINICAL TRIALS 411 6. CONCLUSIONS AND RECOMMENDATIONS 411 REFERENCES
412 CHAPTER 22 BIOAVAILABILITY AND BIOEQUIVALENCE OF TRANSDERMAL DRUG
DELIVERY SYSTEMS: REGULATORY CONSIDERATIONS VINOD P. SHAH, THOMAS M.
LUDDEN, SHRIKANT V. DIGHE, JEROME P. SKELLY, AND ROGER L. WILLIAMS 1.
INTRODUCTION 415 2. NEW DRUG APPLICATIONS 416 2.1. BIOPHARMACEUTICS:
GENERAL ISSUES 416 2.2. PHARMACOKINETICS: GENERAL ISSUES 417 2.3.
CLINICAL PHARMACOLOGY: CONSIDERATIONS 420 2.4. EFFICACY AND SAFETY
REQUIREMENTS 421 2.5. STUDIES REQUIRED FOR TRANSDERMAL DRUG FORMULATIONS
APPROVED FOR OTHER ROUTES OF ADMINISTRATION 422 3. ABBREVIATED NEW DRUG
APPLICATIONS 422 4. CONCLUSIONS 423 REFERENCES 423 XXII CONTENTS CHAPTER
23 ETHICAL AND CLINICAL CONSIDERATIONS FOR TOPICAL DRUG PRODUCTS
(INCLUDING SURGICAL SCRUBS) 425 C. CARNOT EVANS, JR. CHAPTER 24 CLINICAL
CONSIDERATIONS OF TRANSDERMAL DRUGS SOLOMON SOBEL 1. INTRODUCTION 431 2.
CURRENT PROGRESS 432 2.1. ESTROGEN REPLACEMENT THERAPY 432 2.2.
TESTOSTERONE REPLACEMENT 435 3. CONCLUSION 436 INDEX 437
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV009686062 |
| callnumber-first | R - Medicine |
| callnumber-label | RM151 |
| callnumber-raw | RM151 |
| callnumber-search | RM151 |
| callnumber-sort | RM 3151 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| classification_rvk | VX 7580 |
| ctrlnum | (OCoLC)28722190 (DE-599)BVBBV009686062 |
| dewey-full | 615/.6 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615/.6 |
| dewey-search | 615/.6 |
| dewey-sort | 3615 16 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02199nam a2200577 c 4500</leader><controlfield tag="001">BV009686062</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">940705s1993 ad|| |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0306443678</subfield><subfield code="9">0-306-44367-8</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)28722190</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV009686062</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM151</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.6</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VX 7580</subfield><subfield code="0">(DE-625)147815:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Topical drug bioavailability, bioequivalence, and penetration</subfield><subfield code="c">ed. by Vinod P. Shah ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York u.a.</subfield><subfield code="b">Plenum Press</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXII, 453 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biodisponibilité</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biologische beschikbaarheid</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Geneesmiddelentransport</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Médicaments - Équivalence thérapeutique</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peau - Perméabilité</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thérapeutique cutanée et externe</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transdermale toediening</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Administration, Topical</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bioavailability</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological Availability</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Delivery Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Therapeutic equivalency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Skin Absorption</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Skin</subfield><subfield code="x">Permeability</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic Equivalency</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutics, Cutaneous and external</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Transdermales therapeutisches System</subfield><subfield code="0">(DE-588)4194948-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bioäquivalenz</subfield><subfield code="0">(DE-588)4204145-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Bioverfügbarkeit</subfield><subfield code="0">(DE-588)4145660-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Transdermales therapeutisches System</subfield><subfield code="0">(DE-588)4194948-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Bioverfügbarkeit</subfield><subfield code="0">(DE-588)4145660-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Bioäquivalenz</subfield><subfield code="0">(DE-588)4204145-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, Vinod P.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006405650&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006405650</subfield></datafield></record></collection> |
| id | DE-604.BV009686062 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:39:11Z |
| institution | BVB |
| isbn | 0306443678 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006405650 |
| oclc_num | 28722190 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XXII, 453 S. Ill., graph. Darst. |
| publishDate | 1993 |
| publishDateSearch | 1993 |
| publishDateSort | 1993 |
| publisher | Plenum Press |
| record_format | marc |
| spelling | Topical drug bioavailability, bioequivalence, and penetration ed. by Vinod P. Shah ... New York u.a. Plenum Press 1993 XXII, 453 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Biodisponibilité Biologische beschikbaarheid gtt Geneesmiddelentransport gtt Médicaments - Équivalence thérapeutique Peau - Perméabilité Thérapeutique cutanée et externe Transdermale toediening gtt Administration, Topical Bioavailability Biological Availability Drug Delivery Systems Drugs Therapeutic equivalency Skin Absorption Skin Permeability Therapeutic Equivalency Therapeutics, Cutaneous and external Transdermales therapeutisches System (DE-588)4194948-1 gnd rswk-swf Bioäquivalenz (DE-588)4204145-4 gnd rswk-swf Bioverfügbarkeit (DE-588)4145660-9 gnd rswk-swf Transdermales therapeutisches System (DE-588)4194948-1 s Bioverfügbarkeit (DE-588)4145660-9 s Bioäquivalenz (DE-588)4204145-4 s DE-604 Shah, Vinod P. Sonstige oth GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006405650&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Topical drug bioavailability, bioequivalence, and penetration Biodisponibilité Biologische beschikbaarheid gtt Geneesmiddelentransport gtt Médicaments - Équivalence thérapeutique Peau - Perméabilité Thérapeutique cutanée et externe Transdermale toediening gtt Administration, Topical Bioavailability Biological Availability Drug Delivery Systems Drugs Therapeutic equivalency Skin Absorption Skin Permeability Therapeutic Equivalency Therapeutics, Cutaneous and external Transdermales therapeutisches System (DE-588)4194948-1 gnd Bioäquivalenz (DE-588)4204145-4 gnd Bioverfügbarkeit (DE-588)4145660-9 gnd |
| subject_GND | (DE-588)4194948-1 (DE-588)4204145-4 (DE-588)4145660-9 |
| title | Topical drug bioavailability, bioequivalence, and penetration |
| title_auth | Topical drug bioavailability, bioequivalence, and penetration |
| title_exact_search | Topical drug bioavailability, bioequivalence, and penetration |
| title_full | Topical drug bioavailability, bioequivalence, and penetration ed. by Vinod P. Shah ... |
| title_fullStr | Topical drug bioavailability, bioequivalence, and penetration ed. by Vinod P. Shah ... |
| title_full_unstemmed | Topical drug bioavailability, bioequivalence, and penetration ed. by Vinod P. Shah ... |
| title_short | Topical drug bioavailability, bioequivalence, and penetration |
| title_sort | topical drug bioavailability bioequivalence and penetration |
| topic | Biodisponibilité Biologische beschikbaarheid gtt Geneesmiddelentransport gtt Médicaments - Équivalence thérapeutique Peau - Perméabilité Thérapeutique cutanée et externe Transdermale toediening gtt Administration, Topical Bioavailability Biological Availability Drug Delivery Systems Drugs Therapeutic equivalency Skin Absorption Skin Permeability Therapeutic Equivalency Therapeutics, Cutaneous and external Transdermales therapeutisches System (DE-588)4194948-1 gnd Bioäquivalenz (DE-588)4204145-4 gnd Bioverfügbarkeit (DE-588)4145660-9 gnd |
| topic_facet | Biodisponibilité Biologische beschikbaarheid Geneesmiddelentransport Médicaments - Équivalence thérapeutique Peau - Perméabilité Thérapeutique cutanée et externe Transdermale toediening Administration, Topical Bioavailability Biological Availability Drug Delivery Systems Drugs Therapeutic equivalency Skin Absorption Skin Permeability Therapeutic Equivalency Therapeutics, Cutaneous and external Transdermales therapeutisches System Bioäquivalenz Bioverfügbarkeit |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006405650&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT shahvinodp topicaldrugbioavailabilitybioequivalenceandpenetration |